Psoriasis | Treatment Algorithms: Claims Data Analysis | Pediatric Psoriasis | US | 2025

Psoriasis affects pediatric, adolescent, and adult patients similarly; however, the effective management of pediatric psoriasis is more challenging owing to the limited number of treatments approved for children. Only five targeted therapies—Amgen’s Enbrel and Otezla, Johnson & Johnson Innovative Medicine’s Stelara, Eli Lilly’s Taltz, and Novartis’s Cosentyx—are approved to treat pediatric and adolescent psoriasis patients in the United States. Topical corticosteroids continue to be the mainstay of pediatric treatment, but this class is now facing competition from a newer, FDA-approved, nonsteroidal topical cream (Arcutis Biotherapeutics’ Zoryve) in patients six years or older. Additionally, the use of biologics is increasing in pediatric patients, especially in the later lines, owing to the more-frequent and severe adverse events associated with the long-term use of topical corticosteroids in children. Significant unmet need remains for efficacious therapies with improved safety profiles for this psoriasis subpopulation.

QUESTIONS ANSWERED

• What patient shares do key therapies and brands garner by line of therapy in newly diagnosed pediatric psoriasis patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed pediatric psoriasis patients?
• How have biologics such as Enbrel, Humira, Stelara, and Skyrizi and the nonsteroidal topical agents Zoryve and Vtama been integrated into the treatment algorithm, and what is their source of business?
• What percentage of pediatric psoriasis patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
• What percentage of pediatric psoriasis patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
• What are the product-level compliance and persistency rates among drug-treated patients?

Markets covered: United States.

Real-world data: Longitudinal patient-level claims data analysis

Key drugs covered: Enstilar, Duobrii, Humira, Remicade, Stelara, Cosentyx, Taltz, Vtama, Zoryve

Key feature: Dashboard featuring interactive visuals, easy navigation, and expanded analyses

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:

• Understand patient flow between lines of therapy.
• Evaluate your brand share against competitors.
• Accurately assess your source of business.
• Quantify opportunities at different stages of the treatment algorithm.